About Liquidia
A biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Morrisville, NC
- Founded
- 2004
- Company type
- Public Company
- Company profile name
- Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. Liquidia has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia is also developing L606, an investigational liposomal formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer, for use in North America. The subsidiary Liquidia PAH provides for the commercialization of pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection.
Specialties
- biopharmaceuticals
- materials science
- and alternative energy films
Company locations
419 Davis Drive, Suite 100, Morrisville, NC 27560, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
Business areas
- Biotech & Pharmaceuticals
- Pharmaceutical and biotechnology
On LinkedIn
- Followers
- 14,876
- People linked to this company
- 293
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Funding raised
533,399,994 USD
Total reported by Crunchbase, in US dollars. This is funding raised, not company revenue or valuation.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.